Bliss GVS Pharma Allots 55,250 Equity Shares Under ESOP 2019 Scheme
Bliss GVS Pharma Ltd 路 Others (Uncategorized) 路 05 Sept 2026, 12:20 am
Bliss GVS Pharma Allots 55,250 Equity Shares Under ESOP 2019 Scheme Bliss GVS Pharma Limited's ESOP Allotment Committee approved the allotment of 55,250 equity shares (face value Re. 1 each) on 4th Sep'26 following option exercises under the Bliss GVS ESOP-2019 plan. The shares were issued at an exercise price of Rs. 43 per share, including a premium of Rs. 42 per share, subject to a six-month lock-in period expiring 3rd Mar'27. Consequently, the company's paid-up equity share capital increased from Rs. 10,62,75,223 to Rs. 10,63,30,472, comprising 10,63,30,472 equity shares ranking pari passu with existing shares.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. 路 06 Nov 2026
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... 路 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
